Results 11 to 20 of about 626,622 (390)

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

British medical journal, 2021
Objective To assess rates of cardiovascular and haemostatic events in the first 28 days after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S in Denmark and Norway and to compare them with rates observed in the general populations.
A. Pottegård, L. Lund, Ø. Karlstad, J. Dahl, M. Andersen, J. Hallas, Ø. Lidegaard, G. Tapia, H. Gulseth, P. L. Ruiz, S. Watle, A. Mikkelsen, L. Pedersen, H. Sørensen, R. Thomsen, A. Hviid   +15 more
semanticscholar   +1 more source

Increased systemic arterial stiffness in patients with chronic thromboembolic pulmonary hypertension

Cardiology Journal, 2020
BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of venous thromboembolism (VTE) resulting from non-dissolving thromboemboli in the pulmonary arteries.
Monika Sznajder, Olga Dzikowska-Diduch, Katarzyna Kurnicka, Marek Roik, Dominik Wretowski, Piotr Pruszczyk, Maciej Kostrubiec   +6 more
doaj   +1 more source

Incidence of venous thromboembolism in hospitalized patients with COVID‐19

Journal of Thrombosis and Haemostasis, 2020
Coronavirus disease 2019 (COVID‐19) can lead to systemic coagulation activation and thrombotic complications.
S. Middeldorp, M. Coppens, T. V. van Haaps, M. Foppen, A. Vlaar, M. Müller, C. Bouman, L. Beenen, R. Kootte, J. Heijmans, L. Smits, P. Bonta, N. van Es   +12 more
semanticscholar   +1 more source

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Journal of Clinical Oncology, 2020
PURPOSE To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs ...
N. Key, A. Khorana, N. Kuderer, Kari Bohlke, Agnes Y. Y. Lee, J. Arcelus, S. Wong, E. Balaban, C. Flowers, C. Francis, L. Gates, A. Kakkar, M. Levine, H. Liebman, M. Tempero, G. Lyman, A. Falanga   +16 more
semanticscholar   +1 more source

COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms

Thorax, 2021
Thrombotic events that frequently occur in COVID-19 are predominantly venous thromboemboli (VTE) and are associated with increasing disease severity and worse clinical outcomes.
Joan Loo, D. Spittle, M. Newnham
semanticscholar   +1 more source

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

New England Journal of Medicine, 2020
BACKGROUND Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer.
G. Agnelli, C. Becattini, G. Meyer, A. Muñoz, M. Huisman, J. Connors, A. Cohen, R. Bauersachs, B. Brenner, A. Torbicki, M. R. Sueiro, C. Lambert, G. Gussoni, M. Campanini, A. Fontanella, G. Vescovo, M. Verso   +16 more
semanticscholar   +1 more source

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Blood Advances, 2020
BACKGROUND Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States annually. OBJECTIVE These
T. Ortel, I. Neumann, W. Ageno, R. Beyth, N. Clark, A. Cuker, B. Hutten, M. Jaff, Veena Manja, S. Schulman, Caitlin Thurston, S. Vedantham, P. Verhamme, D. Witt, Ivan D. Florez, A. Izcovich, R. Nieuwlaat, S. Ross, Holger J. Schünemann, W. Wiercioch, Yuan Zhang, Yuqing Zhang   +21 more
semanticscholar   +1 more source

Abelacimab for Prevention of Venous Thromboembolism.

New England Journal of Medicine, 2021
BACKGROUND The role of factor XI in the pathogenesis of postoperative venous thromboembolism is uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation.
P. Verhamme, B. Yi, A. Segers, J. Salter, D. Bloomfield, H. Büller, G. Raskob, J. Weitz   +7 more
semanticscholar   +1 more source

Thromboelastography Parameters and Platelet Count on Admission to the ICU and the Development of Venous Thromboembolism in Patients With Coronavirus Disease 2019

Critical Care Explorations, 2021
Objectives:. Determine if thromboelastography parameters and platelet count on the day of ICU admission are associated with the development of venous thromboembolism in patients with coronavirus disease 2019. Design:.
Tanya K. Marvi, MD, William B. Stubblefield, MD, Benjamin F. Tillman, MD, Mark W. Tenforde, MD, PhD, Leora R. Feldstein, PhD, MSc, Manish M. Patel, MD, Wesley H. Self, MD, MPH, Carlos G. Grijalva, MD, MPH, Todd W. Rice, MD, MSc, For the Influenza Vaccine Effectiveness in the Critically Ill (IVY) Investigators   +9 more
doaj   +1 more source

Milvexian for the Prevention of Venous Thromboembolism.

New England Journal of Medicine, 2021
BACKGROUND Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants.
J. Weitz, J. Strony, W. Ageno, D. Gailani, E. Hylek, M. Lassen, K. Mahaffey, Ravi S Notani, R. Roberts, A. Segers, G. Raskob   +10 more
semanticscholar   +1 more source